Sam Brusco, Associate Editor06.14.23
Bioretec, a developer of bioresorbable orthopedic implants, has acquired a new CNC machining center to boost production capacity of RemeOs products at its Tampere, Finland factory.
The acquired CNC machine is optimized for production of magnesium-based implants, especially for the first of the RemeOs product family, the RemeOs screw. The RemeOs screw was awarded U.S. market authorization in March 2023.
"The new CNC machining center will significantly increase our production capacity of RemeOs screws for the U.S. market. We estimate the commissioning of the machine to take place at the beginning of next year considering the current delivery time of 5-6 months. The addition of our own machining center for RemeOs products will also enhance the production of our Activa implants," Bioretec CEO Timo Lehtonen told the press.
Bioretec has built competencies in the biological interface of active implants to boost bone growth and fracture healing after orthopedic surgery. The company’s products are used in about 40 countries worldwide.
RemeOs implants are resorbed and replaced by bone, eliminating the need for removal surgery and facilitating bone healing. According to the company, the combo could make titanium implants redundant and help clinics reach value-based healthcare targets.
Last month, Bioretec brought former White House surgeon and FDA officer Dr. Jeremy Dublon to its team as a regulatory advisor to support the company’s U.S. commercialization strategy from a clinical and regulatory perspective.
The acquired CNC machine is optimized for production of magnesium-based implants, especially for the first of the RemeOs product family, the RemeOs screw. The RemeOs screw was awarded U.S. market authorization in March 2023.
"The new CNC machining center will significantly increase our production capacity of RemeOs screws for the U.S. market. We estimate the commissioning of the machine to take place at the beginning of next year considering the current delivery time of 5-6 months. The addition of our own machining center for RemeOs products will also enhance the production of our Activa implants," Bioretec CEO Timo Lehtonen told the press.
Bioretec has built competencies in the biological interface of active implants to boost bone growth and fracture healing after orthopedic surgery. The company’s products are used in about 40 countries worldwide.
RemeOs implants are resorbed and replaced by bone, eliminating the need for removal surgery and facilitating bone healing. According to the company, the combo could make titanium implants redundant and help clinics reach value-based healthcare targets.
Last month, Bioretec brought former White House surgeon and FDA officer Dr. Jeremy Dublon to its team as a regulatory advisor to support the company’s U.S. commercialization strategy from a clinical and regulatory perspective.